Bioxcel Therapeutics Stock News

NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop trans

BioXcel Therapeutics faces its first PDUFA on April 5.

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transf

BioXCel Therapeutics (BTAI) said that a phase 3 trial of BXCL501 (sublingual dexmedetomidine) for agitation associated with bipolar disorder demonstrated statistically significant changes.

BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo

BioXcel Therapeutics Inc (NASDAQ: BTAI ) announced results from its ongoing Phase 2 trial of BXCL701 in metastatic castration-resistant prostate cancer (mCRPC) patients with either adenocarcinoma or small cell neuroendocrine carcinoma (SCNC) phenotype. Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium. The trial is evaluating the combination of BXCL701 with Merck & Co Inc''s (NYSE: MRK ) Keytruda (pembrolizumab). SCNC Findings: In the evaluable patient cohort (n = 15),

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts

BXCL701 plus KEYTRUDA ® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts

NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran

NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, will present at the upcoming SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16 at 2:20 p.m. ET. Dr. Mehta will highlight the Company’s neuroscience and immuno-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for BXCL501.

XBI: The Worst Is Over

BioXcel Therapeutics: Facing An Important PDUFA Date In A Few Weeks

NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran